PALO ALTO, Calif., March 1 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today reported financial results
for the fourth quarter and full year ended December 31, 2005. For
the quarter ended December 31, 2005, the Company reported a net
loss of $74.1 million, or $1.65 per share, compared to a net loss
of $53.8 million, or $1.62 per share, for the same quarter in 2004.
For the year ended December 31, 2005, the Company reported a net
loss of $228.0 million, or $5.66 per share, compared to a net loss
of $155.1 million, or $4.90 per share, for the year ended December
31, 2004. At December 31, 2005, the Company had cash, cash
equivalents and marketable securities of approximately $460.2
million, compared to $404.5 million at December 31, 2004. Operating
expenses for the quarter ended December 31, 2005 increased to $75.5
million, compared to $60.5 million for the same quarter in 2004.
Operating expenses for the year ended December 31, 2005 increased
to $243.1 million, compared to $167.5 million for the year ended
December 31, 2004. The significant increase in operating expenses
for the quarter as well as the year ended December 31, 2005
compared to the same periods in the prior year were primarily due
to higher selling, general and administrative expenses incurred in
connection with the deployment of the Company's national
cardiovascular specialty sales force and other product support and
awareness programs to co- promote ACEON(R) (perindopril erbumine)
Tablets, as well as higher headcount in other areas to support the
Company's increased commercialization and other business
activities. For the quarter ended December 31, 2005, compared to
the quarter ended December 31, 2004, these higher selling, general
and administrative expenses were partially offset by lower research
and development expenses, primarily due to the 2004 accrual of a
one-time $10.1 million research and development expense due under
our license agreement for ranolazine with Roche Palo Alto LLC and a
decrease in expenses related to the Company's Phase 3 studies of
regadenoson. The Company recognized collaborative research revenue
of $3.4 million for the quarter ended December 31, 2005, compared
to $7.6 million for the same quarter in 2004, and $19.0 million for
the year ended December 31, 2005, compared to $20.4 million for the
year ended December 31, 2004. Revenue recognized primarily relates
to the reimbursement of certain regadenoson development costs from
a collaborative partner and amortization of up-front payments
earned. The Company did not record any co-promotion revenues as
sales of ACEON(R) did not exceed the baseline specified in the
co-promotion agreement with Solvay Pharmaceuticals, Inc. Interest
and other income (expense), net includes interest income from the
Company's investment portfolio, interest expense from convertible
notes, and premium paid above the principal value in the redemption
and repurchase of 4.75% subordinated convertible notes. For the
year ended December 31, 2005, the Company recognized a net expense
of $3.8 million compared to a net expense of $8.0 million for the
same period in 2004. In 2005, the Company earned higher interest
income on the Company's investments and recognized a lower loss for
the August 2005 redemption compared to the May and June 2004
repurchases of 4.75% subordinated convertible notes. The Company
also had lower interest expense in 2005 compared to 2004. Company
management will webcast a conference call on March 1, 2006 at 5:00
p.m. EST, 2:00 p.m. PST, on the Company's website. To access the
live webcast, please log on to the Company's website at
http://www.cvt.com/ and go to the Investor Information section.
Alternatively, domestic callers may participate in the conference
call by dialing (888) 370-6121, and international callers may
participate in the conference call by dialing (706) 679-7163.
Webcast and telephone replays of the conference call will be
available approximately two hours after the completion of the call
through Wednesday, March 8, 2006. Domestic callers can access the
replay by dialing (800) 642-1687, and international callers can
access the replay by dialing (706) 645-9291; the PIN access number
is 5519274. About CV Therapeutics CV Therapeutics, Inc.,
headquartered in Palo Alto, California, is a biopharmaceutical
company focused on applying molecular cardiology to the discovery,
development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases. CV Therapeutics'
approved products include Ranexa(TM) (ranolazine extended-release
tablets) and ACEON(R) (perindopril erbumine) Tablets. Ranexa is
indicated for the treatment of chronic angina in patients who have
not achieved an adequate response with other antianginal drugs, and
should be used in combination with amlodipine, beta-blockers or
nitrates. In addition, CV Therapeutics co-promotes ACEON(R), an ACE
inhibitor, for reduction of the risk of cardiovascular mortality or
nonfatal myocardial infarction in patients with stable coronary
artery disease and treatment of essential hypertension. CV
Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which
is being developed for potential use as a pharmacologic stress
agent in myocardial perfusion imaging studies. Regadenoson has not
been approved for marketing by any regulatory authorities. Except
for the historical information contained herein, the matters set
forth in this press release, including statements as to
development, clinical studies, regulatory review and approval, and
commercialization of products, are forward-looking statements
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause
actual results to differ materially, including, early stage of
development; regulatory review and approval of products; the
conduct and timing of clinical trials; commercialization of
products; market acceptance of products; product labeling; and
other risks detailed from time to time in CV Therapeutics' SEC
reports, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2005. CV Therapeutics disclaims any
intent or obligation to update these forward-looking statements. CV
THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts) (unaudited) Three months
ended Year ended December 31, December 31, 2005 2004 2005 2004
Revenues: Collaborative research $3,432 $7,580 $18,951 $20,428
Operating expenses: Research and development 33,980 48,655 128,448
124,346 Selling, general and administrative 41,534 11,799 114,691
43,178 Total operating expenses 75,514 60,454 243,139 167,524 Loss
from operations (72,082) (52,874) (224,188) (147,096) Interest and
other income (expense), net (1,970) (888) (3,807) (7,987) Net loss
$(74,052) $(53,762) $(227,995) $(155,083) Basic and diluted net
loss per share $(1.65) $(1.62) $(5.66) $(4.90) Shares used in
computing basic and diluted net loss per share 44,884 33,215 40,268
31,671 CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)
December 31, December 31, 2005 2004 (unaudited) (A) Assets: Cash,
cash equivalents and marketable securities $460,183 $404,503 Other
current assets 28,823 23,400 Total current assets 489,006 427,903
Property and equipment, net 20,491 15,284 Other assets 24,949
19,043 Total assets $534,446 $462,230 Liabilities and stockholders'
equity: Current liabilities $63,527 $46,438 Convertible
subordinated notes 399,500 329,645 Other long-term obligations
10,429 6,745 Stockholders' equity 60,990 79,402 Total liabilities
and stockholders' equity $534,446 $462,230 (A) Derived from the
consolidated audited financial statements included in the Company's
Annual Report on Form 10-K/A for the year ended December 31, 2004.
DATASOURCE: CV Therapeutics, Inc. CONTACT: investors, Dan
Spiegelman, SVP & Chief Financial Officer, +1-650-384-8509, or
Christopher Chai, Vice President, Treasury and Investor Relations,
+1-650-384-8560, or media, John Bluth, Senior Director, Corporate
Communications, +1-650-384-8850, all of CV Therapeutics, Inc. Web
site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Aug 2023 to Aug 2024